2025 China Acute Migraine Drugs Market Revenue Opportunities Report
Description
The 2025 China Acute Migraine Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Acute Migraine Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the acute migraine drugs market in China are Teva Pharmaceutical Industries, Eli Lilly and Company, Pfizer Inc, and Amgen Inc. Teva notably advanced with its drug AJOVY (fremanezumab), a CGRP antagonist, achieving positive Phase 3 trial results in China and aiming to meet the large unmet need for migraine prevention. Eli Lilly has been expanding its migraine portfolio with monoclonal antibody therapies such as Emgality, collaborating to increase accessibility in different markets including China. Pfizer is recognized for its nasal spray CGRP antagonist, Zavzpret, approved for acute migraine treatment. Amgen also remains a key player via its portfolio in migraine treatments and research activities targeting the Chinese market.
These companies leverage different drug classes focusing on acute migraine relief, including triptans and CGRP receptor antagonists, which have gained increasing preference due to effectiveness and safety profiles. The China migraine drugs market generated approximately USD 358.6 million in 2024 and is forecasted to rise at a CAGR of 12.4% through 2030, reflecting escalating prevalence with roughly 65 million sufferers nationally. They implement strategies like regulatory approvals of novel therapies, clinical trials in Asian populations, and partnerships to penetrate this fastest-growing regional market segment in Asia Pacific. Overall, these firms shape the evolving landscape by innovating acute migraine treatments and addressing substantial patient demand in China.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Acute Migraine Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the acute migraine drugs market in China are Teva Pharmaceutical Industries, Eli Lilly and Company, Pfizer Inc, and Amgen Inc. Teva notably advanced with its drug AJOVY (fremanezumab), a CGRP antagonist, achieving positive Phase 3 trial results in China and aiming to meet the large unmet need for migraine prevention. Eli Lilly has been expanding its migraine portfolio with monoclonal antibody therapies such as Emgality, collaborating to increase accessibility in different markets including China. Pfizer is recognized for its nasal spray CGRP antagonist, Zavzpret, approved for acute migraine treatment. Amgen also remains a key player via its portfolio in migraine treatments and research activities targeting the Chinese market.
These companies leverage different drug classes focusing on acute migraine relief, including triptans and CGRP receptor antagonists, which have gained increasing preference due to effectiveness and safety profiles. The China migraine drugs market generated approximately USD 358.6 million in 2024 and is forecasted to rise at a CAGR of 12.4% through 2030, reflecting escalating prevalence with roughly 65 million sufferers nationally. They implement strategies like regulatory approvals of novel therapies, clinical trials in Asian populations, and partnerships to penetrate this fastest-growing regional market segment in Asia Pacific. Overall, these firms shape the evolving landscape by innovating acute migraine treatments and addressing substantial patient demand in China.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
